Zacks Investment Research·4 days ago
Here's Why Investors Should Hold IQV Stock in Their Portfolios NowIQVIA's AI tools, record R&D backlog and strong free cash flow support its outlook, but weak liquidity and no dividend remain investor concerns.
IQVIA Holdings Inc.(IQV)Earnings, Financials & Key Ratios
IQV•NYSE
$208.23
26.6× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryContract Research and Preclinical Services
AboutIQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.Show more
- Revenue$16.31B+5.9%
- EBITDA$3.43B+3.5%
- Net Income$1.36B-0.9%
- EPS (Diluted)7.84+4.7%
- Gross Margin26.28%-24.7%
- EBITDA Margin21.04%-2.3%
- Operating Margin14.02%-1.9%
- Net Margin8.34%-6.4%
- ROE21.42%-5.0%
IQV Price & Volume
IQVIA Holdings Inc. (IQV) stock price & volume — 10-year historical chart
Loading chart...
Inconsistent Margin Performance Masks Structural Debt Volatility
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Mixed
Profitability:Moderate
Financial:Strained
Cash Flow:Stable
Primary Risk:High leverage and goodwill
Key Thesis Takeaways
- IQVIA's growth trajectory remains sensitive to pharmaceutical R&D cycles, as evidenced by revenue growth fluctuations between 2.3% and 10.3% over the last ten quarters.
- While the company maintains a robust cash conversion profile with OCF/NI ratios reaching 2.74, investors should monitor the significant reliance on $16.5 billion in goodwill and the recent volatility in debt-to-equity ratios.
- The firm's aggressive share repurchase strategy, including a $1.1 billion outflow in 2024Q4, must be balanced against the risks of constrained operating margins that have struggled to exceed 17%.
Verdict Logic
while the forward P/E of 14.91 suggests potential value, the volatility in debt-to-equity ratios—shifting from 2.44 in 2025Q4 to 0.33 in 2026Q1—warrants further investigation into long-term solvency.
IQV Growth Metrics
IQVIA Holdings Inc. (IQV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.01%
5 Years7.5%
3 Years4.21%
TTM7.32%
Profit CAGR
10 Years13.39%
5 Years37.27%
3 Years7.62%
TTM3.82%
EPS CAGR
10 Years9.79%
5 Years40.54%
3 Years11.08%
TTM9.95%
Return on Capital
10 Years6.96%
5 Years9.62%
3 Years10.63%
Last Year11.01%
IQV Recent Earnings
IQVIA Holdings Inc. (IQV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 11/12 qtrs (92%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$2.90+2.8%
$2.82
Rev
$4.2B+1.2%
$4.1B
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$3.42+0.6%
$3.40
Rev
$4.4B+2.9%
$4.2B
Q4 2025
Oct 28, 2025Metric
Actual
Est
EPS
$3.00+0.7%
$2.98
Rev
$4.1B+0.5%
$4.1B
Q3 2025
Jul 22, 2025Metric
Actual
Est
EPS
$2.81+1.4%
$2.77
Rev
$4.0B+1.2%
$4.0B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $2.90vs $2.82+2.8% | $4.2Bvs $4.1B+1.2% |
| Q1 2026 | Feb 5, 2026 | $3.42vs $3.40+0.6% | $4.4Bvs $4.2B+2.9% |
| Q4 2025 | Oct 28, 2025 | $3.00vs $2.98+0.7% | $4.1Bvs $4.1B+0.5% |
| Q3 2025 | Jul 22, 2025 | $2.81vs $2.77+1.4% | $4.0Bvs $4.0B+1.2% |
Based on last 12 quarters of dataView full earnings history →
Latest IQV News
Recent stock market news and headlines for IQVIA Holdings Inc. (IQV)
Business Wire·Jun 18, 2026
StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare AdvertisingTORONTO--(BUSINESS WIRE)--StackAdapt (www.stackadapt.com), the leading AI advertising and orchestration platform, today announced a collaboration with IQVIA Digital to advance more relevant and compliant engagement with healthcare audiences. IQVIA Digital's integrated solutions enable marketers to quickly transform data-driven insights into meaningful, privacy-conscious activation across the healthcare ecosystem.Through this collaboration, StackAdapt's programmatic advertising capabilities are n.
Forbes·Jun 17, 2026
The Healthcare M&A WaveIn this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Zacks Investment Research·Jun 17, 2026
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
24/7 Wall Street·Jun 17, 2026
Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and MoreFutures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.
Peers Comparison
Key metrics vs top competitors for IQVIA Holdings Inc. (IQV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $208.23 | $35.34B | 26.56 | 5.87% | 8.34% | 21.42% | — | |
| $228.68 | $11.01B | -78.58 | -0.85% | -4.59% | -5.66% | — | |
| $168.72 | $12.92B | 58.18 | -0.37% | 5.35% | 4.7% | — | |
| $25.00 | $1.29B | 25.25 | -2.67% | 6.04% | 4.95% | — | |
| $546.29 | $15.6B | 35.75 | 19.97% | 17.19% | 120.89% | — | |
| $192.30 | $31.24B | 35.35 | 16.34% | 28.37% | 13.36% | — |
Compare IQV vs Peers
IQVIA Holdings Inc. (IQV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IQV SEC Filings & Documents
IQVIA Holdings Inc. (IQV) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 23, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when IQV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IQV Frequently Asked Questions
IQVIA Holdings Inc. (IQV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is IQVIA Holdings Inc.'s revenue?
IQVIA Holdings Inc. (IQV) reported $16.63B in revenue for fiscal year 2025. This represents a 284% increase from $4.33B in 2011.
How fast is IQVIA Holdings Inc. growing?
IQVIA Holdings Inc. (IQV) grew revenue by 5.9% over the past year. This is steady growth.
Is IQV profitable?
Yes, IQVIA Holdings Inc. (IQV) is profitable, generating $1.39B in net income for fiscal year 2025 (8.3% net margin).
Dividend & Returns
What is IQV's return on equity?
IQVIA Holdings Inc. (IQV) has a return on equity (ROE) of 21.4%. This is excellent, indicating efficient use of shareholder capital.
What is IQVIA Holdings Inc.'s free cash flow?
IQVIA Holdings Inc. (IQV) generated $2.67B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.